Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy
- PMID: 18755556
- DOI: 10.1016/j.ijrobp.2008.04.064
Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy
Abstract
Purpose: To evaluate the risk factors for acute esophagitis (AET) in lung cancer patients treated with concurrent 3D-CRT and chemotherapy.
Methods and materials: Data from 100 patients treated with concurrent chemoradiotherapy with a mean dose of 62.05 +/- 4.64 Gy were prospectively evaluated. Esophageal toxicity was graded according to criteria of the Radiation Therapy Oncology Group. The following dosimetric parameters were analyzed: length and volume of esophagus in treatment field, percentage of esophagus volume treated to >or=10, >or=20, >or=30, >or=35, >or=40, >or=45, >or=50, >or=55, and >or=60 Gy, and the maximum (D(max)) and mean doses (D(mean)) delivered to the esophagus. Also, we developed an esophagitis index (EI) to account the esophagitis grades over treatment time.
Results: A total of 59 patients developed AET (Grade 1, 26 patients; Grade 2, 29 patients; and Grade 3, 4 patients). V50 was associated with AET duration (p = 0.017), AET Grade 1 duration (p = 0.016), maximum analgesia (p = 0.019), esophagitis index score (p = 0.024), and AET Grade >or=1 (p = 0.058). If V50 is <30% there is a 47.3% risk of AET Grade >or=1, which increases to 73.3% if V50 is >or=30% (p = 0.008). The predictive abilities of models (sensitivity and specificity) were calculated by receiver operating characeristic curves.
Conclusions: According to the receiver operating characeristic curve analysis, the 30% of esophageal volume receiving >or=50 Gy was the most statistically significant factor associated with AET Grade >or=1 and maximum analgesia (A(max)). There was an association with AET Grade >or=2 but it did not achieve statistical significance (p = 0.076).
Similar articles
-
Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):995-1002. doi: 10.1016/j.ijrobp.2004.12.025. Int J Radiat Oncol Biol Phys. 2005. PMID: 15990000
-
Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1106-12. doi: 10.1016/j.ijrobp.2004.04.051. Int J Radiat Oncol Biol Phys. 2004. PMID: 15519781 Clinical Trial.
-
Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):626-9. doi: 10.1016/j.ijrobp.2005.04.004. Int J Radiat Oncol Biol Phys. 2005. PMID: 15936536
-
Dosimetric and clinical predictors for radiation-induced esophageal injury.Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):335-47. doi: 10.1016/j.ijrobp.2004.06.014. Int J Radiat Oncol Biol Phys. 2005. PMID: 15667951 Review.
-
Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.Semin Oncol. 2004 Dec;31(6 Suppl 18):47-51. doi: 10.1053/j.seminoncol.2004.12.012. Semin Oncol. 2004. PMID: 15726523 Review.
Cited by
-
An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.Radiat Oncol. 2018 Jul 17;13(1):130. doi: 10.1186/s13014-018-1073-3. Radiat Oncol. 2018. PMID: 30016978 Free PMC article.
-
Prediction of Radiation Esophagitis in Non-Small Cell Lung Cancer Using Clinical Factors, Dosimetric Parameters, and Pretreatment Cytokine Levels.Transl Oncol. 2018 Feb;11(1):102-108. doi: 10.1016/j.tranon.2017.11.005. Epub 2017 Dec 18. Transl Oncol. 2018. PMID: 29220828 Free PMC article.
-
Three-dimensional conformal radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: protocol for a systematic review and meta-analysis.BMJ Open. 2024 Nov 7;14(11):e090728. doi: 10.1136/bmjopen-2024-090728. BMJ Open. 2024. PMID: 39515858 Free PMC article.
-
Radiomic and dosimetric parameter-based nomogram predicts radiation esophagitis in patients with non-small cell lung cancer undergoing combined immunotherapy and radiotherapy.Front Oncol. 2024 Dec 18;14:1490348. doi: 10.3389/fonc.2024.1490348. eCollection 2024. Front Oncol. 2024. PMID: 39744008 Free PMC article.
-
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.Front Oncol. 2023 Jul 5;13:1217424. doi: 10.3389/fonc.2023.1217424. eCollection 2023. Front Oncol. 2023. PMID: 37476372 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials